BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
162 hedge funds and large institutions have $419M invested in bluebird bio in 2022 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 58 increasing their positions, 35 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
162
Holders Change
+11
Holders Change %
+7.28%
% of All Funds
2.8%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
36
Increased
58
Reduced
35
Closed
24
Calls
$8.09M
Puts
$6.42M
Net Calls
+$1.68M
Net Calls Change
+$4.36M
Top Buyers
| 1 |
1
State Street
Boston,
Massachusetts
|
$80.5M |
| 2 |
FLSM
2
Frazier Life Sciences Management
Palo Alto,
California
|
$9.12M |
| 3 |
3
Invesco
Atlanta,
Georgia
|
$9.61M |
| 4 |
WP
4
Woodline Partners
San Francisco,
California
|
$7.21M |
| 5 |
5
BlackRock
New York
|
$43.7M |
Top Sellers
| 1 |
1
Wellington Management Group
Boston,
Massachusetts
|
$1.55M |
| 2 |
2
Renaissance Technologies
New York
|
$4.79M |
| 3 |
3
Millennium Management
New York
|
$10.4M |
| 4 |
4
D.E. Shaw & Co
New York
|
$311K |
| 5 |
5
Federated Hermes
Pittsburgh,
Pennsylvania
|
$3.88M |
